克服肿瘤生理病理屏障的纳米药物递送系统的研究进展  

Advances in nano-drug delivery systems overcoming the physiological and pathological barriers of tumor

作　　者：苏志桂[1] 莫然[1] 张灿[1] 

机构地区：[1]中国药科大学江苏省代谢性疾病药物重点实验室,南京210009

出　　处：《中国药科大学学报》2015年第1期28-39,共12页Journal of China Pharmaceutical University

基　　金：国家自然科学基金资助项目(No.81473153;81273468)~~

摘　　要：纳米药物递送系统在肿瘤的靶向治疗中发挥着越来越重要的作用。由于机体的生理特征以及肿瘤的异质性,递送系统从给药到靶点发挥作用需要克服多重生理及病理屏障,包括血液、肿瘤组织、细胞和胞内转运等屏障。本文综述了近年来为克服药物递送屏障提出的新思路与新方法,为设计克服肿瘤生理病理屏障的递送系统、实现对药物的有效递送和肿瘤的高效安全治疗提供理论参考。Nano-drug delivery systems（ nano-DDSs） play an important role in targeted cancer therapy. Due to the physiological characteristics of the body and the heterogenicity of tumor, intravenous delivery of anticancer agents carried by nano-DDSs from the injection site to their targeted sites is required to overcome multiple physiological and pathological barriers, including blood, tumor tissue, tumor cell and intracellular transportation. This review surveys emerging strategies for the development of novel nano-DDSs that can conquer the physiological and pathological barriers of tumor,which provides a great potential platform for safe and efficient cancer treatment.

关 键 词：纳米药物递送系统 生理病理屏障 肿瘤微环境 在体响应 靶向治疗 

分 类 号：R944[医药卫生—药剂学]